| Chinese patent medicine industry is a medicine industry with the most original advantages in China.China has always been committed to promoting and developing the proprietary Chinese medicine industry.However,there are still many difficulties in the development of the Chinese patent medicine industry with a weak industry competitiveness.Therefore,the analysis and evaluation of industrial competitiveness and the identification of the competitive advantages of the proprietary Chinese medicine industry are important links to promote the rapid development of the industry.This study takes the proprietary Chinese medicine industry as the research object,combines the pharmacy management with the industrial economy,and thus conducts a qualitative and quantitative analysis of the competitiveness of China’s proprietary Chinese medicine industry.Objective: To reveal the development level of Chinese patent medicine industry,to enhance the competitiveness of Chinese patent medicine industry and thus put forward suggestions and countermeasures to promote industrial development on the whole.Methods:(1)Data Mining:Through the data mining of the existing proprietary Chinese medicine industry competitiveness literature,such as the former CFDA Domestic Drug Database,the China National Drug Database,the China Statistical Yearbook,and the China High-tech Industry Statistical Yearbook,the industry development and competitiveness status as well as the existing problems are clarified.(2)Mathematical model analysis:Through the establishment of industrial competitiveness evaluation index system,the principal component analysis method is used to calculate the score of industrial competitiveness.Meanwhile,the competitive advantages and disadvantages of Chinese patent medicine industry at present are analyzed with Porter’s "Diamond" model.(3)Through the construction of evaluation indicators,combined with principal component analysis,the competitiveness of Chinese patent medicine industry was studied in longitudinal comparison,and then a horizontal comparison with Chinese chemical manufacturing industry was conducted.Results:(1)Product structure characteristics:There are 9629 kinds of Chinese patent medicines including 59270 batches and 2856 enterprises.The average number of approval numbers per variety is 6.18,and the average number of enterprises per variety is 0.29.Among them,371 were included in the National Essential Drugs Catalogue(2012 edition)and 2126 in the National Medical Insurance Catalogue(2017 edition).A total of 42 formulations are covered,including capsules,tablets,pills,granules,etc with their clinical application amounting to 8 categories such as internal medicine,gynecology,orthopaedics and traumatology,surgery,otorhinolaryngology,dermatology,oncology and ophthalmology for the treatment of 21 kinds of diseases like symptom alleviation,respiratory and digestive diseases.(2)Overview of Domestic Industrial Development:In terms of economic benefits,from 2013 to 2017,the output of Chinese patent medicines increased from 27205,000 to 383,161,000 tons,with an average annual growth rate of 9%;the output of chemical medicines increased from 2633,000 tons to 3554,400 tons,with an average annual growth rate of 8%.The main business income of Chinese patent medicine increased from 506.5 billion yuan to 573.59 billion yuan,with an average annual growth rate of 3%.The main business income of chemical drugs increased from 943.38 billion yuan to 133.23 billion yuan,with an average annual growth rate of 9%.The total profits of Chinese patent medicine increased from 53.84 billion yuan to 70.72 billion yuan,with an average annual growth rate of 7%.The total profits of chemical drugs increased from 93.6 billion yuan to 160.64 billion yuan,with an average annual growth rate of 15%.The annual sales of Chinese patent medicines increased from 198.492 billion yuan to 29.637 billion yuan,with an average annual growth rate of 12%.Among them,Guangdong,Beijing and Zhejiang ranked first in terms of sales income.(3)Overview of International Trade:From 2008 to 2017,China’s total import and export trade of Chinese patent medicines increased from 358 million US dollars to 620 million US dollars,with an average total of 485.3 million US dollars.The trade competition index dropped from-0.0279 to-0.1935,with an average value of-0.049,and the total trade export volume was lower than the import volume.The export of Chinese patent medicine products in China mainly includes five categories: Chinese traditional medicine wine,tablets,Baiyao,refreshing oil and Angong Niuhuang pills.(4)Industrial competitiveness:Based on the analysis of PCA,from 2004 to 2016,the score of industrial competitiveness increased from-2.611 to 2.978,and the overall competitiveness showed an upward trend,but it is still at a low level.Through weight analysis,the top three indicators of industrial factors are R&D expenditure(10,000 yuan),new product sales revenue(10,000 yuan)and new product development projects(items),which indicate that innovation has an irreplaceable role in industrial competitiveness.Through comparative analysis of China’s chemical manufacturing industry,we can see that the international competitiveness of the two major industries are at a low and medium level,but the competitiveness of the latter is rising steadily.The competitiveness of Chinese patent medicine industry fluctuates greatly with an unsteady trend.(5)Advantages and Disadvantages of Industrial Competition:Through the a nalysis of "diamond" model,we can see that:(1)production factors: primary production factors lay a material foundation for industrial competitiveness while a lack of high-level production factors such as high-tech and human resources re sults in weak innovation and R&D capabilities.(2)Market demand: Domestic m arket demand is constantly rising,which is better than international market dev elopment.(3)Relevant and supporting industries: Upstream Chinese medicine indu stry has been well developed,but has not yet formed a complete industrial sca le and management mechanism;meanwhile,pharmaceutical manufacturing industr y,pharmaceutical machinery industry and other related complementary industrie s have created favorable conditions for enhancing the competitiveness of Chine se patent medicine industry.(4)Enterprise structure and strategy: Enterprise devel opment adopts a single strategy with serious product homogeneity.Conclusion: Chinese patent medicines are abundant in varieties and widely used in clinical application,but on the other hand the homogeneity of products is serious,the level of scientific and technological innovation is low,and the proportion of general medicines market and medical insurance market is low.The development trend of industrial scale shows a good sign with the general situation of production and benefit rising at a low speed,which indicates a weak industrial production and on the whole,a weaker development trend than that of chemical industry.It shows that the level of international trade is relatively backward,which is still in the bottleneck period of net import.With a weak competitive disadvantage,the industry’s competitiveness is in the middle and low level,but it has the original advantage of the industry.This paper puts forward the following suggestions to enhance the competitiveness of Chinese patent medicine industry:(1)enhance the level of production factors and strengthen the advantages of production factors;(2)strengthen the protection of intellectual property rights as well as the strategy of international patent distribution;(3)broaden overseas markets and enhance market demand;(4)strengthen the construction of related and supporting industries;(5)Focus on Enterprise Development and Cultivate Big Brand and Big Variety;(6)Strengthen the government’s role in promoting the industry,and improve the top-level design of industrial development. |
PDF Full Text Request